Shares in Outlook Therapeutics cratered today after the FDA rejected the company's marketing application for its lead drug ONS-5010, a therapy for age-related macular dege
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.